Detalhe da pesquisa
1.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Ann Hematol;
2024 Apr 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38609726
2.
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Int J Mol Sci;
20(21)2019 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31683978
3.
Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.
Front Immunol;
13: 819136, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35273601
4.
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Biomolecules;
10(5)2020 04 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32365811
5.
Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells.
Cancers (Basel);
12(2)2020 Jan 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32019102
6.
High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.
Clin Cancer Res;
23(23): 7189-7198, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28928163
7.
Rare gastrointestinal lymphomas: The endoscopic investigation.
World J Gastrointest Endosc;
7(10): 928-49, 2015 Aug 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26265987